8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

May 20, 2008

Date of Report (Date of earliest event reported)

Medistem Laboratories, Inc.

(Exact name of registrant as specified in its charter)

Nevada	333-100137	86-1047317
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.

2223 West Pecos Road, Suite 6, Chandler, Arizona	85224
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:       (954) 727-3662

Not applicable.

(Former name or former address, if changed since last report.)

_____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ] Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 16, 2008, Chris McGuinn resigned from his position as Chief Operating Officer of Medistem Laboratories, Inc. (the “Company”) to pursue other business opportunities. On May 20, 2008, the Company issued a press release announcing Mr. McGuinn’s resignation. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The Company has no current plans for replacing Mr. McGuinn and for the time being will divide his responsibilities among its existing employees.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release regarding Chris McGuinn’s resignation, dated May 20, 2008.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDISTEM LABORATORIES, INC.

Date:  May 20, 2008

By:   /s/ Steve Rivers

Name: Steve Rivers

Title: Chief Financial Officer

3

EX-99

Press Release Source: Medistem Laboratories, Inc.

Medistem Announces Resignation of Chief Operating Officer

Tuesday May 20, 9:05 am ET

SAN DIEGO, CA and SCOTTSDALE, AZ--(MARKET WIRE)--May 20, 2008 -- On May 16, 2008, Chris McGuinn, the Company's Chief Operating Officer, announced his resignation from Medistem Laboratories, Inc.   (OTC BB: MDSM.OB - News) to pursue other business opportunities.

"Chris has been with the Company since its inception and was instrumental in securing the existing management team and developing the Company's strategic direction," stated Thomas Ichim, the Company's Chief Executive Officer. "His efforts have helped to define this organization. We wish Chris the best of luck in his future endeavors."

Chris McGuinn said, "Medistem's talented management team, as well as their novel stem cell type, the endometrial regenerative cell, positions the Company to capture a significant piece of the ever-expanding stem cell therapeutics market. I am proud to have contributed to the foundation of this organization and wish Medistem ongoing success."

The Company has not announced plans for replacing Mr. McGuinn and for the time being will divide his responsibilities among the existing members of the organization.

About Medistem Laboratories

Medistem Laboratories is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction and manipulation for use in treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from menstrual blood. ERCs possess the ability to differentiate into nine tissue types, produce large quantities of growth factors, and can be easily administered without need for invasive procedures. Due to Medistem's relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.

Contact:

Source: Medistem Laboratories, Inc.